

**ORAL HYPOGLYCAEMIC AND ANTI-INFLAMMATORY  
ACTIVITY OF *Pleurotus* MUSHROOMS**

By

**WEERASUNDARA JAYASURIYA ARACHCHILLAGE  
BANUKIE NIROSHA JAYASURIYA**

**Thesis submitted to the University of Sri Jayewardenepura for the  
award of the Degree of Doctor of Philosophy in Biochemistry on  
'Oral hypoglycaemic and anti-inflammatory activity of *Pleurotus*  
mushrooms', on 30<sup>th</sup> September 2013.**



## DECLARATION BY CANDIDATE

The work described in this thesis was carried out by me under the supervision of Dr. T.S. Suresh (Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura), Prof. D.T.U. Abeytunga (Department of Chemistry, Faculty of Science, University of Colombo), Prof. G.H. Fernando (Department of Pharmacology, Faculty of Medical Sciences, University of Sri Jayewardenepura) and Dr. C.A. Wanigatunga (Department of Pharmacology, Faculty of Medical Sciences, University of Sri Jayewardenepura) and a report on this has not been submitted in whole or in part to any university for another Degree/Diploma.

.....08/04/2014.....

Date

.....Ba.....

Signature of candidate

## DECLARATION BY SUPERVISORS

We certify that the above statement made by the candidate is true and that this thesis is suitable for submission to the University for the purpose of evaluation.

*T. S. Suresh*  
8/10/14

Dr. T.S. Suresh

*D.T.U. Abeyunga*  
8/4/14

Prof. D.T.U. Abeyunga

*G.H. Fernando*  
8/4/2014

Prof. G.H. Fernando

*C.A. Wanigatunga*  
8/4/14

Dr. C.A. Wanigatunga

**TO MY PARENTS**

## TABLE OF CONTENTS

<b>I. LIST OF TABLES .....</b>	<b>xvi</b>
<b>II. LIST OF FIGURES .....</b>	<b>xx</b>
<b>III. LIST OF PLATES.....</b>	<b>xxvi</b>
<b>IV. ABBREVIATIONS .....</b>	<b>xxviii</b>
<b>V. ACKNOWLEDGEMENTS .....</b>	<b>xxx</b>
<b>VI. ABSTRACT .....</b>	<b>xxxiv</b>
<b>1. INTRODUCTION .....</b>	<b>1</b>
<b>1.1 Mushrooms as therapeutic agents .....</b>	<b>1</b>
<b>1.2 <i>Pleurotus</i> mushrooms.....</b>	<b>3</b>
1.2.1 <i>P. ostreatus</i> (Jacq.:Fr) P.Kumm .....	5
1.2.2 <i>P. cystidiosus</i> O.K. Miller .....	7
<b>1.3 Diabetes mellitus.....</b>	<b>8</b>
1.3.1 Treatment of diabetes mellitus .....	9
1.3.2 Induction of experimental diabetes .....	12
1.3.3 Intestinal glucose absorption .....	14
<b>1.4 Inflammation .....</b>	<b>14</b>
1.4.1 Models of inflammation .....	16
<b>1.5 Bio assay –guided fractionation .....</b>	<b>17</b>
<b>1.6 Scope of the study .....</b>	<b>18</b>
<b>2. LITERATURE REVIEW .....</b>	<b>23</b>



2.1 Hypoglycaemic activity of mushrooms in rats.....	23
2.2 Hypoglycaemic activity of <i>Pleurotus</i> species in rats.....	23
2.3 Hypoglycaemic activity of mushrooms in humans.....	28
2.4 Hypoglycaemic activity of <i>Pleurotus</i> species in humans.....	28
2.5 Studies conducted to elucidate the mechanism of hypoglycaemic activity .....	29
2.6 Anti-inflammatory activity of mushrooms .....	37
2.7 Anti-inflammatory activity of <i>Pleurotus</i> species.....	37
2.8 Studies conducted to elucidate the mechanism of anti-inflammatory activity ....	40
2.9 Compounds isolated from <i>Pleurotus</i> species.....	41
3. MATERIALS AND METHODS .....	52
3.1 General Methods .....	52
3.1.1 Study setting .....	52
3.1.2 Ethical clearance.....	52
3.1.3 Experimental animals .....	52
3.1.4 Collection of mushrooms .....	53
3.1.5 Determination of moisture content .....	53
3.1.6 Preparation of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> mushrooms .....	53
3.1.7 Extraction of <i>P. ostreatus</i> mushroom.....	55
3.1.8 Fractionation of AE of <i>P. ostreatus</i> mushroom.....	55
3.1.8.1 Hexane fraction of AE of <i>P. ostreatus</i> mushroom (HeFrA).....	55
3.1.8.2 Dichloromethane fraction of AE of <i>P. ostreatus</i> mushroom (DMFrA) .....	57
3.1.8.3 Aqueous fraction of AE of <i>P. ostreatus</i> mushroom (AqFrA).....	57
3.1.9 Oral feeding .....	57

3.1.10 Collection of blood .....	57
3.1.11 Determination of serum glucose.....	57
3.1.12 Determination of serum levels of haemoglobin (Hb) and HbA1c in rats.....	59
3.1.13 Determination of serum levels of alanine amino transferase (ALT) in rats and humans.....	60
3.1.14 Determination of serum levels of aspartate amino transferase (AST) in rats and humans.....	61
3.1.15 Determination of serum levels of alkaline phosphatase (ALP) in humans.....	62
3.1.16 Determination of serum levels of gamma glutamyl transferase( $\gamma$ -GT) in rats and humans.....	62
3.1.17 Determination of serum levels of creatinine in rats and humans .....	63
3.1.18 Determination of serum levels of insulin in rats .....	64
3.1.19 Determination of serum levels of insulin in humans.....	66
3.1.20 Determination of serum levels of GK in rats.....	68
3.1.21 Determination of serum levels of GSK in rats .....	70
3.1.22 Induction of experimental diabetes .....	70
<b>3.2 Evaluation of oral hypoglycaemic activity of the SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> culinary mushrooms in normoglycaemic healthy Wistar rats .....</b>	<b>71</b>
3.2.1 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in normoglycaemic healthy Wistar rats .....	71
3.2.2 Effect of different doses of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in normoglycaemic healthy Wistar rats .....	71

3.2.3 Optimal time of action of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in normoglycaemic healthy Wistar rats .....	72
3.2.4 Effect of multiple doses of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in normoglycaemic healthy Wistar rats .....	72
3.2.5 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in comparison to antidiabetic drugs using normoglycaemic healthy Wistar rats .....	72
3.2.6 Effect of long term administration of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> on HbA1c levels of normoglycaemic healthy Wistar rats .....	73
<b>3.3 Evaluation of oral hypoglycaemic activity of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> culinary mushrooms in alloxan- induced diabetic Wistar rats .....</b>	<b>73</b>
3.3.1 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in alloxan-induced diabetic male Wistar rats .....	73
3.3.2 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> mushrooms in comparison to antidiabetic drugs using alloxan- induced diabetic male Wistar rats ....	74
3.3.3 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> using alloxan-induced diabetic female Wistar rats in different stages of oestrous cycle .....	74
3.3.4 Effect of long term administration of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in comparison with antidiabetic drugs using alloxan- induced diabetic male Wistar rats	76
3.3.5 Effect of long term administration of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> on the body weights of alloxan- induced diabetic male Wistar rats in comparison with antidiabetic drugs .....	76
<b>3.4 Oral hypoglycaemic activity of extracts and fractions of <i>P. ostreatus</i> evaluated by activity-guided methods .....</b>	<b>77</b>



3.4.1 Effect of a single dose of AE of <i>P. ostreatus</i> in normoglycaemic healthy Wistar rats .....	77
3.4.2 Effect of a single dose of AE of <i>P. ostreatus</i> in alloxan- induced diabetic male Wistar rats.....	77
3.4.3 Effect of HeFrA, DMFrA and AqFrA (arising from AE of <i>P. ostreatus</i> ) in normoglycaemic healthy Wistar rats .....	77
3.4.4 Effect of fractions of Fr <sub>a</sub> , Fr <sub>b</sub> , Fr <sub>c</sub> and Fr <sub>d</sub> (arising from AqFrA of <i>P. ostreatus</i> ) in normoglycaemic healthy Wistar rats .....	78
3.4.5 Effect of sub fractions Fr <sub>1</sub> , Fr <sub>2</sub> , Fr <sub>3</sub> , Fr <sub>4</sub> and Fr <sub>5</sub> (arising from combined Fr <sub>c</sub> and Fr <sub>d</sub> ) in normoglycaemic healthy Wistar rats.....	80
3.4.6 Effect of sub fractions Fr <sub>1-1</sub> , Fr <sub>1-2</sub> , Fr <sub>1-3</sub> and Fr <sub>1-4</sub> (arising from Fr <sub>1</sub> ) in normoglycaemic healthy Wistar rats .....	80
<b>3.5 Effect of long term administration of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> culinary mushrooms on serum levels of key hepatic enzymes, creatinine and Hb using healthy Wistar rats.....</b>	<b>82</b>
<b>3.6 The probable mechanisms of oral hypoglycaemic activity of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> culinary mushrooms evaluated using normoglycaemic healthy Wistar rats and alloxan- induced diabetic Wistar rats.....</b>	<b>83</b>
3.6.1 Effect of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> on intestinal glucose absorption using normoglycaemic healthy Wistar rats .....	83
3.6.2 Effect of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> on intestinal glucose absorption and serum levels of insulin, GK and GSK using alloxan- induced diabetic Wistar rats .....	83

<b>3.7 Studies with healthy volunteers and diabetic patients, on diet control.....</b>	<b>84</b>
3.7.1 Effect of multiple doses of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> mushrooms in healthy volunteers.....	84
3.7.2 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in diabetic patients, on diet control .....	85
<b>3.8 Evaluation of the anti-inflammatory activity of SFDP <i>P. ostreatus</i> and AE of <i>P. ostreatus</i> .....</b>	<b>87</b>
3.8.1 Anti-inflammatory activity of <i>P. ostreatus</i> in healthy Wistar rats using different doses of SFDP <i>P. ostreatus</i> and AE of <i>P. ostreatus</i> in comparison with indomethacin .....	87
3.8.2 Anti-inflammatory activity of <i>P. ostreatus</i> in alloxan-induced diabetic Wistar rats using SFDP <i>P. ostreatus</i> and AE of <i>P. ostreatus</i> in comparison with indomethacin....	89
<b>3.9 Evaluation of mechanisms of anti-inflammatory activity of AE of <i>P. ostreatus</i> in healthy Wistar rats.....</b>	<b>89</b>
3.9.1 Antihistamine activity .....	89
3.9.2 Assay for carrageenan induced infiltration of rat peritoneal cells.....	90
3.9.3 <i>In vivo</i> assay for NO production by peritoneal cells .....	90
3.9.4 <i>In vitro</i> assay for NO production by peritoneal cells .....	91
3.9.5 Assay for membrane stabilizing activity .....	93
<b>3.10 Anti-inflammatory activity of extracts and fractions of AE of <i>P. ostreatus</i> evaluated by activity-guided methods .....</b>	<b>93</b>

3.10.1 Anti-inflammatory activity of HeFrA, DMFrA and AqFrA (arising from AE of <i>P. ostreatus</i> ) in healthy Wistar rats using carrageenan-induced rat paw oedema model .....	93
3.10.2 Anti-inflammatory activity of fractions of Fr <sub>a</sub> , Fr <sub>b</sub> , Fr <sub>c</sub> and Fr <sub>d</sub> (arising from AqFrA of <i>P. ostreatus</i> ) in healthy Wistar rats using carrageenan-induced rat paw oedema model.....	94
3.10.3 Anti-inflammatory activity of fractions of Fr <sub>a</sub> , Fr <sub>b</sub> , Fr <sub>c</sub> and Fr <sub>d</sub> (arising from AqFrA of <i>P. ostreatus</i> ) using chemiluminescence assay .....	94
3.10.4 Anti-inflammatory activity of sub fractions Fr <sub>1</sub> , Fr <sub>2</sub> , Fr <sub>3</sub> , Fr <sub>4</sub> and Fr <sub>5</sub> (arising from combined Fr <sub>c</sub> and Fr <sub>d</sub> ) in healthy Wistar rats using carrageenan-induced rat paw oedema model.....	96
3.10.5 Anti-inflammatory activity of sub fractions Fr <sub>1</sub> , Fr <sub>2</sub> , Fr <sub>3</sub> , Fr <sub>4</sub> and Fr <sub>5</sub> (arising from combined Fr <sub>c</sub> and Fr <sub>d</sub> ) using chemiluminescence assay .....	96
3.10.6 Anti-inflammatory activity of sub fractions Fr <sub>1-1</sub> , Fr <sub>1-2</sub> , Fr <sub>1-3</sub> and Fr <sub>1-4</sub> (arising from Fr <sub>1</sub> ) in healthy Wistar rats using carrageenan-induced rat paw oedema model....	96
3.10.7 Anti-inflammatory activity of sub fractions Fr <sub>1-1</sub> , Fr <sub>1-2</sub> , Fr <sub>1-3</sub> and Fr <sub>1-4</sub> (arising from Fr <sub>1</sub> ) using chemiluminescence assay .....	97
<b>3.11 Isolation and characterization of compounds.....</b>	<b>97</b>
3.11.1 Isolation and characterization of compound G.....	97
3.11.2 Isolation and characterization of compound 5.....	99
3.11.3 Isolation and characterization of compound A.....	99
3.11.4 Isolation and characterization of compounds C <sub>2</sub> and D <sub>1</sub> .....	100
<b>3.12 Anti-inflammatory activity of compounds.....</b>	<b>100</b>



3.12.1 Anti-inflammatory activity of isolated pure compounds (G, 5, A, C <sub>2</sub> and D <sub>1</sub> ) using chemiluminescence assay .....	100
3.12.2 Anti-inflammatory activity of compounds in healthy Wistar rats using carrageenan-induced rat paw oedema model .....	101
<b>3.13 Statistical analysis .....</b>	<b>101</b>
<b>4. RESULTS .....</b>	<b>102</b>
<b>4.1 Determination of the moisture content .....</b>	<b>102</b>
<b>4.2 Evaluation of oral hypoglycaemic activity of the SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> culinary mushrooms in normoglycaemic healthy Wistar rats .....</b>	<b>102</b>
4.2.1 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in normoglycaemic healthy Wistar rats .....	102
4.2.2 Effect of different doses of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in normoglycaemic healthy Wistar rats .....	104
4.2.3 Optimal time of action of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in normoglycaemic healthy Wistar rats .....	107
4.2.4 Effect of multiple doses of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> mushrooms in normoglycaemic healthy Wistar rats .....	107
4.2.5 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in comparison to antidiabetic drugs using normoglycaemic healthy Wistar rats .....	111
4.2.6 Effect of long term administration of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> on HbA1c levels of normoglycaemic healthy Wistar rats .....	111
<b>4.3 Evaluation of oral hypoglycaemic activity of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> culinary mushrooms in alloxan- induced diabetic Wistar rats .....</b>	<b>113</b>



4.3.1 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in alloxan - induced diabetic male Wistar rats.....	113
4.3.2 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> mushrooms in comparison to antidiabetic drugs using alloxan-induced diabetic male Wistar rats ...	113
4.3.3 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> using alloxan-induced diabetic female Wistar rats in different stages of oestrous cycle.....	115
4.3.4 Effect of long term administration of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in comparison with antidiabetic drugs using alloxan- induced diabetic male Wistar rats .....	118
4.3.5 Effect of long term administration of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 500 mg/kg respectively on the body weights of alloxan-induced diabetic male Wistar rats in comparison with antidiabetic drugs .....	122
<b>4.4 Oral hypoglycaemic activity of extracts and fractions of <i>P. ostreatus</i> evaluated by activity-guided methods.....</b>	<b>122</b>
4.4.1 Effect of a single dose of AE of <i>P. ostreatus</i> in normoglycaemic healthy Wistar rats .....	122
4.4.2 Effect of a single dose of AE of <i>P. ostreatus</i> in alloxan-induced diabetic male Wistar rats.....	124
4.4.3 Effect of HeFrA, DMFrA and AqFrA (arising from AE of <i>P. ostreatus</i> ) in normoglycaemic healthy Wistar rats .....	124
4.4.4 Effect of fractions of Fr <sub>a</sub> , Fr <sub>b</sub> , Fr <sub>c</sub> and Fr <sub>d</sub> (arising from AqFrA of <i>P. ostreatus</i> ) in normoglycaemic healthy Wistar rats .....	127

4.4.5 Effect of sub fractions Fr <sub>1</sub> , Fr <sub>2</sub> , Fr <sub>3</sub> , Fr <sub>4</sub> and Fr <sub>5</sub> (arising from combined Fr <sub>c</sub> and Fr <sub>d</sub> ) in normoglycaemic healthy Wistar rats.....	127
4.4.6 Effect of sub fractions Fr <sub>1-1</sub> , Fr <sub>1-2</sub> , Fr <sub>1-3</sub> and Fr <sub>1-4</sub> (arising from Fr <sub>1</sub> ) in normoglycaemic healthy Wistar rats.....	129
<b>4.5 Effect of long term administration of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> culinary mushrooms on serum levels of key hepatic enzymes, creatinine and Hb using healthy Wistar rats.....</b>	<b>129</b>
<b>4.6 The probable mechanisms of oral hypoglycaemic activity of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> culinary mushrooms evaluated using normoglycaemic healthy Wistar rats and alloxan- induced diabetic Wistar rats.....</b>	<b>131</b>
4.6.1 Effect of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> on intestinal glucose absorption using normoglycaemic healthy Wistar rats .....	131
4.6.2 Effect of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> on intestinal glucose absorption and serum levels of insulin, GK and GSK using alloxan- induced diabetic Wistar rats .....	133
<b>4.7 Studies with healthy volunteers and diabetic patients, on diet control.....</b>	<b>139</b>
4.7.1 Effect of multiple doses of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> mushrooms in healthy volunteers.....	139
4.7.2 Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in diabetic patients, on diet control .....	142
<b>4.8 Evaluation of the anti-inflammatory activity of SFDP <i>P. ostreatus</i> and AE of <i>P. ostreatus</i>.....</b>	<b>146</b>

4.8.1 Anti-inflammatory activity of <i>P. ostreatus</i> in healthy Wistar rats using different doses of SFDP <i>P. ostreatus</i> and AE of <i>P. ostreatus</i> in comparison with indomethacin .....	146
4.8.2 Anti-inflammatory activity of <i>P. ostreatus</i> in alloxan-induced diabetic Wistar rats using SFDP <i>P. ostreatus</i> and AE of <i>P. ostreatus</i> in comparison with indomethacin..	149
<b>4.9 Evaluation of mechanisms of anti-inflammatory activity of AE of <i>P. ostreatus</i> in healthy Wistar rats.....</b>	<b>152</b>
4.9.1 Antihistamine activity .....	152
4.9.2 Assay for carrageenan induced infiltration of rat peritoneal cells.....	152
4.9.3 <i>In vivo</i> assay for NO production by peritoneal cells .....	154
4.9.4 <i>In vitro</i> assay for NO production by peritoneal cells .....	154
4.9.5 Assay for membrane stabilizing activity .....	157
<b>4.10 Anti-inflammatory activity of extracts and fractions of AE of <i>P. ostreatus</i> evaluated by activity-guided methods .....</b>	<b>161</b>
4.10.1 Anti-inflammatory activity of HeFrA, DMFrA and AqFrA (arising from AE of <i>P. ostreatus</i> ) in healthy Wistar rats using carrageenan-induced rat paw oedema model .....	161
4.10.2 Anti-inflammatory activity of fractions of Fr <sub>a</sub> , Fr <sub>b</sub> , Fr <sub>c</sub> and Fr <sub>d</sub> (arising from AqFrA of <i>P. ostreatus</i> ) in healthy Wistar rats using carrageenan-induced rat paw oedema model.....	164
4.10.3 Anti-inflammatory activity of fractions of Fr <sub>a</sub> , Fr <sub>b</sub> , Fr <sub>c</sub> and Fr <sub>d</sub> (arising from AqFrA of <i>P. ostreatus</i> ) using chemiluminescence assay .....	167



4.10.4 Anti-inflammatory activity of sub fractions Fr <sub>1</sub> , Fr <sub>2</sub> , Fr <sub>3</sub> , Fr <sub>4</sub> and Fr <sub>5</sub> (arising from combined Fr <sub>c</sub> and Fr <sub>d</sub> ) in healthy Wistar rats using carrageenan-induced rat paw oedema model.....	167
4.10.5 Anti-inflammatory activity of sub fractions Fr <sub>1</sub> , Fr <sub>2</sub> , Fr <sub>3</sub> , Fr <sub>4</sub> and Fr <sub>5</sub> (arising from combined Fr <sub>c</sub> and Fr <sub>d</sub> ) using chemiluminescence assay .....	171
4.10.6 Anti-inflammatory activity of sub fractions Fr <sub>1-1</sub> , Fr <sub>1-2</sub> , Fr <sub>1-3</sub> and Fr <sub>1-4</sub> (arising from Fr <sub>1</sub> ) in healthy Wistar rats using carrageenan-induced rat paw oedema model..	171
4.10.7 Anti-inflammatory activity of sub fractions Fr <sub>1-1</sub> , Fr <sub>1-2</sub> , Fr <sub>1-3</sub> and Fr <sub>1-4</sub> (arising from Fr <sub>1</sub> ) using chemiluminescence assay .....	175
<b>4.11 Isolation and characterization of compounds.....</b>	<b>177</b>
4.11.1 Isolation and characterization of compound G.....	177
4.11.2 Isolation and characterization of compound 5.....	182
4.11.3 Isolation and characterization of compound A.....	190
4.11.4 Isolation and characterization of compound C <sub>2</sub> and D <sub>1</sub> .....	196
<b>4.12 Anti-inflammatory activity of compounds.....</b>	<b>204</b>
4.12.1 Anti-inflammatory activity of compounds (G, 5, A, C <sub>2</sub> and D <sub>1</sub> ) using chemiluminescence assay .....	204
4.12.2 Anti-inflammatory activity of compounds in healthy Wistar rats using carrageenan-induced rat paw oedema model .....	204
<b>5. DISCUSSION .....</b>	<b>209</b>
<b>6. CONCLUSIONS .....</b>	<b>241</b>
<b>7. REFERENCES.....</b>	<b>244</b>
<b>8. APPENDICES .....</b>	<b>277</b>



8.1 Appendix 1-Publications and communications .....	277
8.2 Appendix 2 - $^1\text{H}$ NMR of compound G.....	282
8.3 Appendix 3 - $^{13}\text{C}$ NMR (BB) of compound G .....	283
8.4 Appendix 4 - $^{13}\text{C}$ NMR (DEPT 135) of compound G .....	284
8.5 Appendix 5 - $^{13}\text{C}$ NMR (DEPT 90) of compound G .....	285
8.6 Appendix 6 -2D NMR (COSY) of compound G .....	286
8.7 Appendix 7 -2D NMR (NOESY) of compound G .....	287
8.8 Appendix 8 - 2D NMR (HMBC) of compound G.....	288
8.9 Appendix 9 - 2D NMR (HSQC) of compound G.....	289
8.10 Appendix 10 - EI+ Mass spectrum of compound G .....	290
8.11 Appendix 11 - $^1\text{H}$ NMR of compound $\text{D}_1$ .....	291
8.12 Appendix 12 - $^{13}\text{C}$ NMR (BB) of compound $\text{D}_1$ .....	292
8.13 Appendix 13 - $^{13}\text{C}$ NMR (DEPT 135) of compound $\text{D}_1$ .....	293
8.14 Appendix 14 - $^{13}\text{C}$ NMR (DEPT 90) of compound $\text{D}_1$ .....	294
8.15 Appendix 15 -2D NMR (COSY) of compound $\text{D}_1$ .....	295
8.16 Appendix 16 -2D NMR (NOESY) of compound $\text{D}_1$ .....	296
8.17 Appendix 17 - 2D NMR (HMBC) of compound $\text{D}_1$ .....	297
8.18 Appendix 18 - 2D NMR (HSQC) of compound $\text{D}_1$ .....	298
8.19 Appendix 19 - EI+ Mass spectrum of compound $\text{D}_1$ .....	299
8.20 Appendix 20 - $^1\text{H}$ NMR of compound $\text{C}_2$ .....	300
8.21 Appendix 21 - $^{13}\text{C}$ NMR (BB) of compound $\text{D}_1$ .....	301
8.22 Appendix 22 - $^{13}\text{C}$ NMR (DEPT 90) of compound $\text{C}_2$ .....	302
8.23 Appendix 23 - $^{13}\text{C}$ NMR (DEPT 135) of compound $\text{C}_2$ .....	303

8.24 Appendix 24 -2D NMR (COSY) of compound C <sub>2</sub> .....	304
8.25 Appendix 25 -2D NMR (NOESY) of compound C <sub>2</sub> .....	305
8.26 Appendix 26 - 2D NMR (HMBC) of compound C <sub>2</sub> .....	306
8.27 Appendix 27 - 2D NMR (HSQC) of compound C <sub>2</sub> .....	307
8.28 Appendix 28 - EI+ Mass spectrum of compound C <sub>2</sub> .....	308
8.29 Appendix 29 - <sup>1</sup> H NMR of compound A .....	309
8.30 Appendix 30 - <sup>13</sup> C NMR (BB) of compound A .....	310
8.31 Appendix 31 - <sup>13</sup> C NMR (DEPT 90) of compound A .....	311
8.32 Appendix 32 - <sup>13</sup> C NMR (DEPT 135) of compound A .....	312
8.33 Appendix 33 -2D NMR (COSY) of compound A .....	313
8.34 Appendix 34 -2D NMR (NOESY) of compound A .....	314
8.35 Appendix 35 - 2D NMR (HMBC) of compound A .....	315
8.36 Appendix 36 - 2D NMR (HSQC) of compound A .....	316
8.37 Appendix 37 - ESI Mass spectrum of compound A .....	317
8.38 Appendix 38 - <sup>1</sup> H NMR of compound 5 .....	318
8.39 Appendix 39 - <sup>13</sup> C NMR (BB) of compound 5 .....	319
8.40 Appendix 40 - <sup>13</sup> C NMR (DEPT 90) of compound 5 .....	320
8.41 Appendix 41 - <sup>13</sup> C NMR (DEPT 135) of compound 5 .....	321
8.42 Appendix 42 -2D NMR (COSY) of compound 5 .....	322
8.43 Appendix 43 -2D NMR (NOESY) of compound 5 .....	323
8.44 Appendix 44- 2D NMR (HMBC) of compound 5 .....	324
8.45 Appendix 45 - 2D NMR (HSQC) of compound 5 .....	325
8.46 Appendix 46- EI+ Mass spectrum of compound 5 .....	326

<b>8.47 Appendix 47 – Ethical clearance for rat study .....</b>	<b>327</b>
<b>8.48 Appendix 48 - Ethical clearance for human study .....</b>	<b>328</b>
<b>8.49 Appendix 49 – Trial Registration Confirmation Letter .....</b>	<b>329</b>
<b>8.50 Appendix 50 – Completion of NAM S &amp; T Fellowship.....</b>	<b>330</b>



## I. LIST OF TABLES

		Page No
Table 1.1	Categories of increased risk for diabetes	9
Table 4.1	Effect of different doses (250 -1250 mg/kg) of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in normoglycaemic healthy Wistar rats	105
Table 4.2	Time course of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 500 mg/kg respectively, in normoglycaemic Wistar rats	108
Table 4.3	Effect of multiple doses of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> in normoglycaemic healthy Wistar rats at a dose of 500 mg/kg respectively	110
Table 4.4	Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> (at a dose of 500 mg/kg respectively) mushrooms using alloxan-induced diabetic female Wistar rats in different stages of oestrous cycle	117
Table 4.5	Effect of long term administration of SFDP <i>P. ostreatus</i> , <i>P. cystidiosus</i> (at a dose of 500 mg/kg respectively) and metformin (15 mg/kg) on fasting and postprandial serum glucose levels in alloxan-induced diabetic male Wistar rats	119
Table 4.6	Effect of long term administration of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 500 mg/kg respectively, on serum levels of key hepatic enzymes (ALT, AST and $\gamma$ -GT), creatinine and	130



	Hb using healthy Wistar rats	
Table 4.7	Effect of multiple doses of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 50 mg/kg respectively, in healthy volunteers	140
Table 4.8	Effect of multiple doses of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 50 mg/kg respectively, on serum levels of key hepatic enzymes (ALT, AST, ALP and $\gamma$ -GT) and creatinine as well as creatinine clearance of healthy volunteers	141
Table 4.9	Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 50 mg/kg respectively, on serum levels of key hepatic enzymes (ALT, AST, ALP and $\gamma$ -GT) and creatinine as well as creatinine clearance of diabetic patients, on diet control	145
Table 4.10	Inhibition of carrageenan induced rat paw oedema, following oral administration of different doses of SFDP <i>P. ostreatus</i> (at a dose range of 125 – 1000 mg/kg), AE of <i>P. ostreatus</i> (500 mg/kg) and indomethacin (10 mg/kg) using healthy rats	147
Table 4.11	Inhibition of carrageenan induced rat paw oedema, following oral administration of different doses of SFDP <i>P. ostreatus</i> (at doses of 500 and 1000 mg/kg), AE of <i>P. ostreatus</i> (500 mg/kg) and indomethacin (10 mg/kg) using alloxan- induced diabetic Wistar rats	150
Table 4.12	Inhibition of carrageenan induced rat paw oedema, following oral administration of HeFrA, DMFrA and AqFrA (arising from	162

	AE of <i>P. ostreatus</i> ) at a dose of 500 mg/kg respectively and indomethacin (10 mg/kg) using healthy rats	
Table 4.13	Inhibition of carrageenan induced rat paw oedema, following oral administration of fractions of Fr <sub>a</sub> , Fr <sub>b</sub> , Fr <sub>c</sub> and Fr <sub>d</sub> (arising from AqFrA of <i>P. ostreatus</i> ) at a dose of 100 mg/kg respectively using healthy rats	165
Table 4.14	The effect of fractions of Fr <sub>a</sub> , Fr <sub>b</sub> , Fr <sub>c</sub> and Fr <sub>d</sub> (arising from AqFrA of <i>P. ostreatus</i> ) on reactive oxidative burst of human whole blood	168
Table 4.15	Inhibition of carrageenan induced rat paw oedema, following oral administration of sub fractions Fr <sub>1</sub> , Fr <sub>2</sub> , Fr <sub>3</sub> , Fr <sub>4</sub> and Fr <sub>5</sub> (arising from combined Fr <sub>c</sub> and Fr <sub>d</sub> ) at a dose of 10 mg/kg respectively in healthy rats	169
Table 4.16	The effect of sub fractions Fr <sub>1</sub> , Fr <sub>2</sub> , Fr <sub>3</sub> , Fr <sub>4</sub> and Fr <sub>5</sub> (arising from combined Fr <sub>c</sub> and Fr <sub>d</sub> ) on reactive oxidative burst of human whole blood	172
Table 4.17	Inhibition of carrageenan induced rat paw oedema, following oral administration of sub fractions Fr <sub>1-1</sub> , Fr <sub>1-2</sub> , Fr <sub>1-3</sub> and Fr <sub>1-4</sub> (arising from Fr <sub>1</sub> ) at a dose of 1 mg/kg respectively, using healthy rats	173
Table 4.18	The effect of sub fractions Fr <sub>1-1</sub> , Fr <sub>1-2</sub> , Fr <sub>1-3</sub> and Fr <sub>1-4</sub> (arising from Fr <sub>1</sub> ) on reactive oxidative burst of human whole blood	176

Table 4.19	$^{13}\text{C}$ NMR data of compound G and Kojibiose	178
Table 4.20	$^{13}\text{C}$ NMR data of compound G and Nigerose	178
Table 4.21	$^{13}\text{C}$ NMR data of compound G and Gentiobiose	178
Table 4.22	The $^1\text{H}$ NMR coupling constant of compound G, Kojibiose, Nigerose and Gentiobiose	179
Table 4.23	The $^1\text{H}$ and $^{13}\text{C}$ -NMR assignments and HSQC, HMBC and COSY correlations of compound 5	185
Table 4.24	$^1\text{H}$ NMR data of compound 5 in comparison to $^1\text{H}$ NMR data of uridine and pseudouridine	188
Table 4.25	$^{13}\text{C}$ -NMR data of compound 5 in comparison to $^{13}\text{C}$ -NMR data of uridine and pseudouridine	189
Table 4.26	The $^1\text{H}$ and $^{13}\text{C}$ -NMR assignments and HSQC, HMBC and COSY correlations of compound A	193
Table 4.27	The $^1\text{H}$ and $^{13}\text{C}$ -NMR assignments and HSQC, HMBC and COSY correlations of compound D <sub>1</sub>	198
Table 4.28	The $^1\text{H}$ and $^{13}\text{C}$ -NMR assignments and HSQC, HMBC and COSY correlations of compound C <sub>2</sub>	202
Table 4.29	The effect of isolated pure compounds on reactive oxidative burst of human whole blood	205
Table 4.30	Inhibition of carrageenan induced rat paw oedema, following oral administration of compounds A, 5 (at a dose of 1 mg/kg respectively) and indomethacin (10 mg/kg) using healthy rats	207



## II. LIST OF FIGURES

		Page No
Figure 2.1	Chemical structure of chrysin by Jayakumar <i>et al.</i> , (2009)	35
Figure 2.2	Chemical structure of ganoderol B by Fatmawati <i>et al.</i> , (2011)	35
Figure 2.3	Chemical structure of inotodiol by Lu <i>et al.</i> , (2010)	36
Figure 2.4	Chemical structure of trametenolic acid by Lu <i>et al.</i> , (2010)	36
Figure 2.5	Chemical structure of cordycepin by Shin <i>et al.</i> , (2009)	36
Figure 2.6	The structure of the repeating unit of the heteropolysaccharide from <i>P. ostreatus</i> isolated by Maity <i>et al.</i> , (2011)	42
Figure 2.7	The structure of the repeating unit of the polysaccharide from <i>P. ostreatus</i> isolated by Sun and Liu, 2009	42
Figure 2.8	The structure of the repeating unit of the polysaccharide from <i>P. ostreatus</i> isolated by Tong <i>et al.</i> , (2009)	46
Figure 2.9	The structure of the repeating unit of the $\beta$ -glucan from <i>P. pulmonarius</i> isolated by Smiderle <i>et al.</i> , (2008)	46
Figure 2.10	The structure of the repeating unit of the 3- <i>O</i> -methylated mannogalactan of <i>P. pulmonarius</i> isolated by Smiderle <i>et al.</i> , (2008)	48
Figure 2.11	The structure of the repeating unit of the polysaccharide of <i>P. abalonus</i> isolated by Wang <i>et al.</i> , (2011)	48
Figure 2.12	Chemical structure of 3b, 5a,6b-trihydroxyergosta-7,22-diene by Menikpurage <i>et al.</i> , (2009)	48

Figure 4.1	Oral hypoglycaemic effect of a single dose of SFDP <i>P. ostreatus</i> at a dose of 1000 mg/kg and <i>P. cystidiosus</i> at a dose of 500 mg/kg in normoglycaemic Wistar rats	103
Figure 4.2	Dose-response curves of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> (250 -1250 mg/kg) in normoglycaemic Wistar rats	106
Figure 4.3	Comparison of the oral hypoglycaemic effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 500 mg/kg respectively, with that of metformin (15 mg/kg) and glibenclamide (0.1 mg/kg) in normoglycaemic Wistar rats	112
Figure 4.4	Oral hypoglycaemic effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 500 mg/kg respectively, on alloxan-induced diabetic male Wistar rats	114
Figure 4.5	Comparison of the oral hypoglycaemic effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 500 mg/kg respectively, with that of metformin (15 mg/kg) and glibenclamide (0.1 mg/kg) using alloxan- induced diabetic male Wistar rats	116
Figure 4.6	Effect of long term administration of <i>P. ostreatus</i> (500 mg/kg), <i>P. cystidiosus</i> (500 mg/kg) and metformin (15 mg/kg) on glycated haemoglobin levels on day 42 using alloxan- induced diabetic rats	121
Figure 4.7	Effect of long term administration of <i>P. ostreatus</i> (500 mg/kg), <i>P. cystidiosus</i> (500 mg/kg) and metformin (15 mg/kg) on body weight of diabetic rats	123

Figure 4.8	Effect of a single dose of AE of <i>P. ostreatus</i> at a dose of 500 mg/kg in normoglycaemic healthy, Wistar rats and in alloxan-induced diabetic male Wistar rats	125
Figure 4.9	Effect of HeFrA, DMFrA and AqFrA (arising from AE of <i>P. ostreatus</i> ) at a dose of 500 mg/kg respectively, in normoglycaemic healthy Wistar rats	126
Figure 4.10	Effect of fractions of Fr <sub>a</sub> , Fr <sub>b</sub> , Fr <sub>c</sub> and Fr <sub>d</sub> (arising from AqFrA of <i>P. ostreatus</i> ) at a dose of 100 mg/kg respectively, in normoglycaemic healthy Wistar rats	128
Figure 4.11	Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 500 mg/kg respectively, on the intestinal glucose absorption of healthy male Wistar rats following a glucose challenge	132
Figure 4.12	Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 500 mg/kg respectively, on the intestinal glucose absorption of alloxan- induced diabetic male Wistar rats following a glucose challenge	135
Figure 4.13	Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 500 mg/kg respectively, on postprandial serum insulin levels of alloxan- induced diabetic male Wistar rats	136



Figure 4.14	Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 500 mg/kg respectively, on postprandial serum GK levels of alloxan-induced diabetic male Wistar rats	137
Figure 4.15	Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 500 mg/kg respectively, on postprandial serum GSK levels of alloxan- induced diabetic male Wistar rats	138
Figure 4.16	Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 50 mg/kg respectively, on postprandial serum glucose levels of diabetic patients, on diet control	143
Figure 4.17	Effect of a single dose of SFDP <i>P. ostreatus</i> and <i>P. cystidiosus</i> at a dose of 50 mg/kg respectively, on postprandial serum insulin levels of diabetic patients, on diet control	144
Figure 4.18	Percentage inhibition of carrageenan induced rat paw oedema, following oral administration of different doses of SFDP <i>P. ostreatus</i> (at a dose range of 125 – 1000 mg/kg), AE of <i>P. ostreatus</i> (500 mg/kg) and indomethacin (10 mg/kg) using healthy rats	148
Figure 4.19	Inhibition of carrageenan induced rat paw oedema, following oral administration of different doses of SFDP <i>P. ostreatus</i> at doses of 500 and 1000 mg/kg, AE of <i>P. ostreatus</i> (500 mg/kg) and indomethacin (10 mg/kg) using alloxan- induced diabetic Wistar rats	151

Figure 4.20	Inhibition of carrageenan induced infiltration of rat peritoneal cells by AE of <i>P. ostreatus</i> (500 mg/kg) and prednisolone (10 mg/kg)	153
Figure 4.21	Inhibition of NO production by peritoneal cells following <i>in vivo</i> treatment of AE of <i>P. ostreatus</i> (500 mg/kg) and prednisolone (10 mg/kg).	155
Figure 4.22	Effect of different concentrations of AE of <i>P. ostreatus</i> (at a dose range of 3.90 – 125.0 µg/mL) on NO production by rat peritoneal cells	158
Figure 4.23	Percentage inhibition of heat-induced haemolysis of rat erythrocytes by AE of <i>P. ostreatus</i> and aspirin (at a dose range of 0.001 – 1000.0 µg/mL)	160
Figure 4.24	Percentage inhibition of carrageenan induced rat paw oedema, following oral administration of AqFrA of <i>P. ostreatus</i> (500 mg/kg) and indomethacin (10 mg/kg) using healthy rats	163
Figure 4.25	Percentage inhibition of carrageenan induced rat paw oedema, following oral administration of Fr <sub>c</sub> and Fr <sub>d</sub> fractions at a dose of 100 mg/kg respectively using healthy rats	166
Figure 4.26	Percentage inhibition of carrageenan induced rat paw oedema, following oral administration of Fr <sub>1</sub> , Fr <sub>2</sub> , and Fr <sub>5</sub> at a dose of 10 mg/kg respectively, using healthy rats	170

Figure 4.27	Percentage inhibition of carrageenan induced rat paw oedema, following oral administration of Fr <sub>1-1</sub> and Fr <sub>1-2</sub> at a dose of 1.0 mg/kg respectively, using healthy rats	174
Figure 4.28	The structure of Gentiobiose	181
Figure 4.29	Compound 5 with <sup>1</sup> H and <sup>13</sup> C NMR	183
Figure 4.30	Compound 5 with 2D NMR HMBC data	184
Figure 4.31	Structure of pseudouridine	187
Figure 4.32	Compound A with <sup>1</sup> H and <sup>13</sup> C NMR	191
Figure 4.33	Compound A with 2D NMR HMBC data	192
Figure 4.34	Possible mass spectral fragmentation mechanisms for compound A	195
Figure 4.35	Compound D <sub>1</sub> with <sup>1</sup> H, <sup>13</sup> C NMR and 2D NMR HMBC data	197
Figure 4.36	Possible mass spectral fragmentation mechanisms for compound D <sub>1</sub>	199
Figure 4.37	Compound C <sub>2</sub> with <sup>1</sup> H, <sup>13</sup> C NMR and 2D NMR HMBC data	201
Figure 4.38	Possible mass spectral fragmentation mechanisms for compound C <sub>2</sub>	203
Figure 4.39	Percentage inhibition of carrageenan induced rat paw oedema, following oral administration of compounds A, 5 (at a dose of 1 mg/kg respectively) and indomethacin (10 mg/kg) using healthy rats	208



### III. LIST OF PLATES

		PageNo.
Plate 1.1	<i>P. ostreatus</i> (Jacq.:Fr) P.Kumm	5
Plate 1.2	<i>P. cystidiosus</i> O.K. Miller	7
Plate 3.1	Housing of rats	54
Plate 3.2	Wistar male rats	54
Plate 3.3	Freeze dried and powdered <i>P. ostreatus</i>	56
Plate 3.4	Freeze dried and powdered <i>P. cystidiosus</i>	56
Plate 3.5	Oral feeding	58
Plate 3.6	Drawing of blood from lateral tail vein of a rat	58
Plate 3.7	Introducing a drop of normal saline into the vagina of a female rat to determine the stage of the oestrous cycle	75
Plate 3.8	Passage of the aqueous fraction of acetone extract of <i>P. ostreatus</i> through Sephadex LH 20 column	79
Plate 3.9	Passage of the combined Fr <sub>c</sub> and Fr <sub>d</sub> fractions through silica column	81
Plate 3.10	Passage of fraction Fr <sub>1</sub> through a silica column	81
Plate 3.11	Packeted freeze dried and powdered <i>P. ostreatus</i> used in the clinical study	86
Plate 3.12	Packeted freeze dried and powdered <i>P. cystidiosus</i> used in the clinical study	86

Plate 3.13	Administration of carrageenan subcutaneously into the plantar surface of the hind paw of rat	88
Plate 3.14	Measurement of the volume of the hind paw of rat using a plethysmometer	88
Plate 3.15	Draining of peritoneal fluid using an 18 G cannula from rat peritoneal cavity	92
Plate 3.16	Chemiluminescence assay	98
Plate 4.1	Production of NO by peritoneal cells harvested from rats following oral administration of acetone extract of <i>P.</i> <i>ostreatus</i> and prednisolone	156
Plate 4.2	Production of NO by peritoneal cells treated with different concentrations of AE of <i>P. ostreatus in vitro</i>	159

#### IV. ABBREVIATIONS

AE	Acetone extract
ABM	<i>Agaricus blazei</i> Murill
ALT	Alanine amino transferase
ALP	Alkaline phosphatase
AqFrA	Aqueous fraction of acetone extract
AST	Aspartate amino transferase
BB	Broad band
BSA	Bovine serum albumin
b.w.	Body weight
Con A	Concanavalin A
COSY	Correlation spectroscopy
COX	Cyclooxygenase
DPP-4	Dipeptidyl peptidase-4
DEPT	Distortionless enhancement by polarization transfer
DMFrA	Dichloromethane fraction of acetone extract
EAF	Ethyl acetate fraction
ELISA	Enzyme-linked immunosorbent assay
FPG	Fasting plasma glucose
$\gamma$ -GT	Gamma glutamyl transferase
GIP	Glucagon-like insulintropic peptide
GLP-1	Glucagon-like peptide -1



GK	Glucokinase
GKA	Glucokinase activators
GLUT	Glucose transporter
GSK	Glycogen synthase kinase
GSKI	Glycogen synthase kinase inhibitors
Hb	Haemoglobin
HbA1c	Glycated haemoglobin
HBSS	Hank's balanced salt solution
HeFrA	Hexane fraction of acetone extract
HMBC	Heteronuclear multiple-bond correlation spectroscopy
HOMA-IR	Homeostasis model assessment of insulin resistance
HPLC	High performance liquid chromatography
HRP	Horseradish peroxidase
HSQC	Heteronuclear single quantum coherence spectroscopy
IDDM	Insulin dependent diabetes mellitus
IFG	Impaired fasting glycaemia
IFN	Interferon
IGT	Impaired glucose tolerance
IL	Interleukin
iNOS	Inducible nitric oxide synthase
i.p.	Intraperitoneal
LPS	Lipopolysaccharide
NF- $\kappa$ B	Nuclear transcription factor

NIDDM	Non-insulin-dependent diabetes
NMR	Nuclear magnetic resonance
NO	Nitric oxide
NOESY	Nuclear overhauser effect spectroscopy
NSAIDs	Non-steroidal anti-inflammatory drugs
NSS	Normal sterile saline
OD	Optical density
OGTT	Oral glucose tolerance test
PBS	Phosphate buffered saline
PG	Prostaglandin
Pp-aqu	Aqueous extract of <i>Pleurotus pulmonarius</i>
RBC	Red blood cell
RLU	Relatively light unit
ROS	Reactive oxygen species
SFDP	Suspensions of freeze dried and powdered
SOZ	Serum opsonized zymosan
TNF- $\alpha$	Tumour necrosis factor- $\alpha$

## V. ACKNOWLEDGEMENTS

I wish to thank all those who contributed in different ways to the work involving my thesis.

My warm and deep appreciation is extended to my research supervisors, Dr. T.S. Suresh, Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka, Prof. D.T.U. Abeytunga, Department of Chemistry, Faculty of Science, University of Colombo, Sri Lanka, Prof. G.H. Fernando, Department of Pharmacology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka and Dr. C.A. Wanigatunga, Department of Pharmacology, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka, for their invaluable guidance, patience, constant advice, support and encouragement given throughout this endeavour.

I would like to express my sincere thanks and heartfelt gratitude to Dr. S.M. Handunnetti, Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo, Sri Lanka, for her excellent supervision and training given to me during the research work at Institute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo, Sri Lanka and especially for giving me the opportunity to utilize the facilities available at the institution.

Grateful acknowledgement is extended to Prof. M. Iqbal Choudhary, Director, ICCBS, University of Karachi, Pakistan for giving me an opportunity to do my research work at ICCBS, a world famous institute under the NAM S & T-ICCBS fellowship. Further, I am deeply appreciative of his excellent supervision, constant guidance and training provided to



me during compound isolation studies, and giving me the opportunity to utilize the facilities available in the institution. I greatly appreciate the enduring support and kind co-operation extended to me by his graduate students and staff especially Ms. M. Khan for training me in the operation of recycling HPLC during my stay at Pakistan.

Sincere gratitude to Dr. A.L.P. De. S. Senevirathna, Head, Department of Family Medicine, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka for the help extended to me in recruiting the diabetic patients. I greatly appreciate the enduring support extended by Mrs. A. Jayawardena and Ms. M.C.K. Jayarathne in the form of phlebotomy assistance.

My grateful thanks go to Prof. S. Ekanayake, the Head, Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka and the academic and non- academic staff members and research students of the Department of Biochemistry, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka for the numerous support provided in many ways.

My heartfelt thanks to the staff of the Animal Centre, MRI, Colombo and Animal House, Faculty of Medical Sciences, University of Sri Jayewardenepura, Sri Lanka for the training, enduring support and kind co-operation extended during the research work and providing the necessary facilities to carry out the study.

My profound thanks to the healthy and diabetic volunteers for volunteering to take part in the clinical study without which this project would not have been a success.

My sincere appreciation is also extended to University of Sri Jayewardenepura, Sri Lanka for providing financial assistance through the University Research Grant scheme (ASP/06/Re/2008/04) and World Class University Project (Ph.D./04/2012) granted to the principal supervisor Dr. T.S. Suresh. I am also grateful to Center for Science and Technology of the Non-aligned and other developing countries, India for providing me NAM S & T-ICCBS fellowship for travel and training under well respected researchers at ICCBS, University of Karachi, Pakistan.

I am grateful to National Science Foundation, Sri Lanka for providing me financial assistance under the travel grant scheme which enabled me to travel abroad to present my research findings.

My heartfelt thanks to the Librarian and library staff of University of Sri Jayewardenepura, Sri Lanka and ICCBS, University of Karachi, Pakistan for the services rendered.

Special word of thanks is extended to Mrs. K.D.K.P. Kumari, Dr. S. Hapuarachchi and Mrs. L. Herath for assistance and encouragement given to me throughout the study. Special thanks are due to Mrs. S.P. Fernando for supporting me in many ways during my stay at ICCBS, University of Karachi, Pakistan.

In addition I am forever grateful to my parents and my husband, for their patience, greatest support and encouragement extended to me throughout the study. I dedicate this thesis to my parents. Special thanks go out to my daughter, Vidara for her patience during my absence. Last but not least, warm thanks go to all my colleagues, for helping me in many ways.

## ORAL HYPOGLYCAEMIC AND ANTI-INFLAMMATORY ACTIVITY OF *Pleurotus* MUSHROOMS

WEERASUNDARA JAYASURIYA ARACHCHILLAGE BANUKIE  
NIROSHA JAYASURIYA

### ABSTRACT

This study investigates the oral hypoglycaemic activity of the culinary mushrooms *Pleurotus ostreatus* and *P. cystidiosus* and the anti-inflammatory activity of *P. ostreatus*.

Oral hypoglycaemic activity of *P. ostreatus* and *P. cystidiosus* was investigated in normal and alloxan-induced diabetic Wistar rats. The suspensions of freeze-dried and powdered *P. ostreatus* and *P. cystidiosus* possess significant hypoglycaemic activity which was comparable with metformin and glibenclamide. The maximally effective dose was 500 mg/kg for both mushrooms. Optimal time of activity was 120 minutes after administration of suspensions of *P. ostreatus* and *P. cystidiosus*. Hypoglycaemic effect of *P. ostreatus* and *P. cystidiosus* (500 mg/kg) was investigated using diabetic female rats at different stages of the oestrous cycle. The highest hypoglycaemic effect was found at the proestrous stage for both mushrooms. Both short and long term administration of suspensions of freeze-dried and powdered *P. ostreatus* and *P. cystidiosus* exerted an apparent control on the homeostasis of blood glucose of diabetic rats. Severe reduction of weight which is characteristic of uncontrolled diabetes was significantly reduced in mushroom groups ( $p < 0.05$ ). The hypoglycaemic effect was retained in the acetone extract which reduced the postprandial serum glucose levels significantly ( $p < 0.05$ ) in normal and diabetic rats.



Experiments were directed to elucidate the mechanism of action of hypoglycaemic activity. Administration of suspensions of *P. ostreatus* and *P. cystidiosus* to diabetic rats increased the intestinal absorption of glucose but simultaneously reduced the serum glucose levels. The mushrooms reduced the serum levels of glycogen synthase kinase and promoted insulin secretion when compared with the Control group ( $p < 0.05$ ). Further, there was a significant increase in serum levels of glucokinase in *P. cystidiosus* group when compared with the Control group ( $p = 0.02$ ). Thus, it could be postulated that *P. ostreatus* and *P. cystidiosus* exert the oral hypoglycaemic activity via several possible mechanisms viz increasing glucokinase activity, increasing insulin secretion, promoting glycogen synthesis and increasing glucose utilization by peripheral tissues. Long term feeding of mushrooms to rats did not show signs of liver and renal toxicity.

This study was focused further to determine the efficacy and safety of *P. ostreatus* and *P. cystidiosus* in healthy volunteers and patients with Type 2 diabetes on diet control. Administration of mushroom suspensions at daily dosages of 50 mg/kg for 2 weeks showed a significant reduction ( $p < 0.05$ ) in fasting and postprandial serum glucose levels of healthy volunteers. *Pleurotus ostreatus* and *P. cystidiosus* (50 mg/kg) significantly ( $p < 0.01$ ) reduced the postprandial serum glucose levels and increased the serum insulin levels ( $p < 0.05$ ) of patients with Type 2 diabetes on diet control. Healthy volunteers and patients with Type 2 diabetes on diet control were monitored for one month after receiving *P. ostreatus* and *P. cystidiosus* for any adverse effects. There were no significant difference ( $p > 0.05$ ) in the serum levels of liver enzymes and creatinine as well as estimated creatinine clearance of subjects after one month.

The anti-inflammatory potential of *P. ostreatus* in normal and alloxan- induced diabetic Wistar rats was investigated using the carrageenan-induced rat paw oedema model. The suspensions of freeze-dried and powdered *P. ostreatus* and acetone extract of *P. ostreatus* significantly ( $p < 0.05$ ) inhibited the carrageenan induced paw oedema and the effect was comparable to that of indomethacin.

Anti-inflammatory activity of *P. ostreatus* in rats is mediated via multiple mechanisms viz antihistamine and membrane stabilizing activity, inhibition of cell migration to the site of inflammation and inhibition of nitric oxide production.

The acetone extract of *P. ostreatus* was subjected to an anti-inflammatory activity guided fractionation to identify the fraction having the highest activity. Extracts and fractions were tested for anti-inflammatory activity using the carrageenan-induced paw oedema assay in rats and the *in vitro* Luminol based chemiluminescence assay. The acetone extract of *P. ostreatus* was sequentially fractionated with solvents with increasing polarity. The residual aqueous fraction of the acetone extract showed significant ( $p < 0.05$ ) anti-inflammatory activity in both models. The active fractions were identified and the compounds were isolated by size exclusion, normal and reverse phase column chromatography and recycling HPLC techniques. Spectroscopic analysis of the isolated compounds were done by MS,  $^1\text{H}$ NMR,  $^{13}\text{C}$ NMR and 2DNMR (COSY, NOESY, HMBC, HMQC). A disaccharide, a derivative of uridine, N<sup>10</sup> isopentenyl adenosine, niacinamide and uracil were isolated from *P. ostreatus*. The derivative of uridine and novel isolated compound N<sup>10</sup> isopentenyl adenosine compounds possess significant ( $p < 0.05$ ) anti-inflammatory activity in rats.

In conclusion, this study suggests that consumption of *P. ostreatus* and *P. cystidiosus* will bring health benefits to mankind and these culinary mushrooms can be popularized as functional foods.